LY2181308 Sodium

LY2181308 Sodium · Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LY2181308 Sodium, covering 2019-06-11 to 2019-06-11. Get the full timeline:

Most recent: Clinical Trial Update: A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 2]